Plasma Glucose Kinetics and Cereal Product Content in Slowly Digestible Starch (SDS) in Healthy Volunteers

September 13, 2017 updated by: Mondelēz International, Inc.

Plasma Glucose Kinetics Following Ingestion of Two Cereal Products With a Different Content in Slowly Digestible Starch (SDS) in Healthy Males and Females

The present study aims at investigating the effect of ingesting 2 cereal products differing by their SDS content on the kinetics of glucose in healthy volunteers.

Study Overview

Status

Completed

Detailed Description

The present study will compare the effect of consuming cereal products alone on :

  • the rates of appearance and disappearance of exogenous and total glucose
  • the glycemic and insulinemic responses
  • the postprandial GIP concentrations

Study Type

Interventional

Enrollment (Actual)

41

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Quebec
      • Montréal, Quebec, Canada, H2W1R7
        • Institut de Recherches Cliniques de Montreal

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 38 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Healthy volunteer, male or female (half male, half female);
  • Aged between 18 and 40 years old (bounds included);
  • Non-smoker;
  • BMI ranging between 18.5 and 25 kg/m2 (bounds included)
  • Waist circumference ≤ 94 cm for men and ≤ 80 cm for women;
  • Stable body weight (± 1 kg) over the 3 months preceding the experimental period;
  • Systolic blood pressure between 95 and 145 mmHg and diastolic blood pressure between 50 and 85 mmHg;
  • For the female subjects: use of an oral contraceptive with regular menstrual cycles;
  • Subject not displaying any identified significant metabolic impairment according to the Principal Investigator;
  • Sedentary or with a moderate physical activity;
  • Not having given blood in the month prior to the selection and accepting not to give blood during the experimental period of the present study;
  • Regularly consuming a breakfast providing more than 15% of the total daily energy intake, including at least one cereal product; adequate partitioning of macronutrient intake;
  • Providing written consent for his/her participation to the study;

Exclusion Criteria:

  • Subject with a severe or acute disease which should influence the results of the study and to be life-threatening for the volunteer according to the Principal Investigator;
  • Subject with medical history of symptomatic vascular diseases (infarct, angina pectoris, syndrome of threat, surgery or endovascular surgery, stroke, symptomatic peripheral arteritis) which according to the investigator should interfere with the results from the study or should constitute a particular risk for the subject;
  • Subject with type 1 or type 2 diabetes;
  • Subject with any food allergy;
  • Subject with eating disorders (e.g. anorexia nervosa & bulimia) according to the Principal Investigator;
  • Subject regularly consuming more than 20 g/day of alcohol;
  • Subject regularly consuming recreational drugs;
  • Subject consuming regularly corticoids, anorectics, adrenergic drugs, gastric demulcent, cholesterol and/or lipid lowering medication, weight-loss drugs or other drugs or supplement that should impact glucose metabolism in the Principal Investigator's opinion;
  • Pregnant or lactating women;
  • Currently participating in another study or having participated in another study in the 3 months prior to the selection visit;
  • Consuming large amounts of food products naturally rich in 13C.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: High-SDS biscuit
Biscuit with high Slowly Digestible Starch content
acute evaluation of the effect of ingestion of cereal products differing by their Slowly Digestible Starch content
Active Comparator: Low-SDS cereal product
Cereal product with low Slowly Digestible Starch content
acute evaluation of the effect of ingestion of cereal products differing by their Slowly Digestible Starch content

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rate of appearance of exogenous glucose (RaE)
Time Frame: T0 to 300 minutes
Postprandial kinetic of RaE
T0 to 300 minutes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
iAUC RaE
Time Frame: T0 to 300 minutes
iAUC of RaE over selected intervals over the 300-minute postprandial period
T0 to 300 minutes
kinetics of Rate of disappearance of exogenous glucose (RdE), Rate of appearance of total glucose (RaT), Rate of disappearance of total glucose (RdT) and Endogenous glucose production (EGP)
Time Frame: T0 to 300 minutes
Postprandial kinetics of RdE, RaT, RdT and EGP
T0 to 300 minutes
iAUC of RdE, RaT, RdT and EGP
Time Frame: T0 to 300 minutes
iAUC of RdE, RaT and RdT and dAUC of EGP over selected intervals over the 300-minute postprandial period
T0 to 300 minutes
kinetics of glycemia and insulinemia
Time Frame: T-120 to 300 minutes
Pre- and postprandial kinetics of glycemia and insulinemia
T-120 to 300 minutes
iAUC of glycemia and insulinemia
Time Frame: T0 to 300 minutes
iAUC of glycemia and insulinemia over selected intervals over the 300-minute postprandial period
T0 to 300 minutes
Kinetics of plasma glucose-dependent insulinotropic peptide (GIP) concentration
Time Frame: T0 to 300 minutes
Postprandial kinetic of GIP
T0 to 300 minutes
iAUC of GIP
Time Frame: T0 to 300 minutes
iAUC of GIP over selected intervals over the 300-minute postprandial period
T0 to 300 minutes
Kinetics of plasma FFA concentration
Time Frame: T0 to 300 minutes
Postprandial kinetic of FFA
T0 to 300 minutes
dAUC of FFA
Time Frame: T0 to 300 minutes
dAUC of FFA over selected intervals over the 300-minute postprandial period
T0 to 300 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Remi Rabasa-Llhoret, MD, PhD, Institut de Recherches Cliniques de Montreal

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2015

Primary Completion (Actual)

December 1, 2015

Study Completion (Actual)

April 1, 2016

Study Registration Dates

First Submitted

December 18, 2014

First Submitted That Met QC Criteria

December 22, 2014

First Posted (Estimate)

December 23, 2014

Study Record Updates

Last Update Posted (Actual)

September 14, 2017

Last Update Submitted That Met QC Criteria

September 13, 2017

Last Verified

September 1, 2017

More Information

Terms related to this study

Other Study ID Numbers

  • KBE032

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Blood Glucose Kinetics

Clinical Trials on Nutrition intervention with cereal products

3
Subscribe